

**Michigan Pharmacy and Therapeutics Committee  
Minutes, September 13, 2006 Meeting**

**Introductions**

The Committee members present were: Khan Nedd, MD, Justus Fiechtner, MD, Paul Dake, MD, Jonathon Arend, PharmD, Erin Inman, PharmD, Dean VanLoo, PharmD, Neil Dorfman, PharmD. Ronald Bradley, DO, Giovannino Perri, MD. Rockelle Rogers, MD had an excused absence.

In addition, the Drug Utilization Review Board was invited to participate with the Committee. Board members present were Duane Kirking, PhD, Steve Bernstein, MD, Dawn Parsons, RPh, Karen Jonas, RPh, Debera Eggleston, MD, Sahar Suidan, PharmD. Other State staff present were Jacqueline Coleman, Pharmacy Policy Specialist and Tom Welch, Pharmacy Analyst. Karen Parker, RPh, Clinical Pharmacist, First Health Services Corporation was also in attendance. Dr. Kirking gave an overview of the DUR Board for the benefit of the Committee and the public present.

**Approval of Minutes**

The minutes of the June 6, 2006 meeting were approved by the Committee.

**New Drug Reviews**

Following presentation by Karen Parker of the synopses of the new drugs, available to the Committee in their packets, the following recommendations were made to the Department:

- Ranexa®**: add to the Michigan Pharmaceutical Product List (MPPL) with step edits to look for nitrates, amlodipine and/or beta blockers
- Taclonex®**: Add to the MPPL with age and quantity edits
- Chantix®**: Add to the MPPL using monthly quantity limits and the course of therapy in its licensure
- Femtrace®**: Add to the MPPL with prior authorization
- Sprycel®**: Add to the MPPL
- Apidra®, Levemir®, Exubera®**: see discussion under Review of Preferred Drug List (PDL) Classes

**Line Extensions**

Following presentation and review, the Committee recommended the following:

- Ultram ER®**: add to the MPPL and PDL with prior authorization
- BonivaIV®**: This will be billed as a physician service
- Xodol 5/300®**: add to the MPPL and PDL with prior authorization
- AmbienCR®**: add to the MPPL and PDL with prior authorization

**Review of PDL Classes**

Following review and extensive discussion, the Committee recommends to the Department the following:

**Beta Adrenergics, Short Acting** (carryover from June)

- Add Xopenex HFA® without PA
- Monitor quantity limits for use of these rescue medications for asthma
- No change to other listings

**Diabetes Drug Classes**

- Amylin Analogs**: no change to current PDL

**Secretin Mimetics:** no change to current PDL

**Oral Hypoglycemics-Alpha Glucosidase Inh:** no change to current PDL

**Oral Hypoglycemics-Biguanides:** no change to current PDL

**Oral Hypoglycemics-Meglitinides:** no change to current PDL

**Insulins:** Subdivide this large class into five: Basal Insulins, Rapid acting Insulins, Insulin Mixes, Traditional Insulins, Inhaled Insulins

For **Basal Insulins**, add Levemir® and Lantus® without PA

For **Rapid Acting Insulins**, add Apidra®, Humalog®, Novolog® without PA

For **Insulin Mixes**, add Humalog 50/50®, Humalog 75/25®, Humulin 50/50®, Novolin 70/30®, Novolog 70/30®, Humulin 70/30® without PA

For **Traditional Insulins**, add Humulin L®, Humulin R500U®, Humulin U®, Novolin L®, Novolin N®, Novolin R®, Velosulin BR® without PA; continue PA for Humulin N®, Humulin R®, Iletin I Lente®, Iletin I N®, Iletin I R®, Iletin II Pork®, Iletin II Pork N®, Iletin II Pork R®

For **Inhaled Insulins**, add Exubera® without PA, but with an edit at Point of Service (POS) that would require a PA if there are previous or concomitant prescriptions for inhalers used for pulmonary diseases

**Oral Hypoglycemics-Biguanide Combinations:** change name to Oral Hypoglycemics-Combinations; do not change current listing of drug products

**Oral Hypoglycemics-2<sup>nd</sup> Generation Sulfonylureas:** add Glimiperide without PA; no changes to current listings

**Oral Hypoglycemics-Thiazolidinediones:** Remove PA from Avandia®

#### **Gastrointestinal Drug Classes**

**Nausea Agents-Oral:** Create a new class for Emend®, termed Substance P Receptor Antagonist, and remove PA from Emend®

**Proton Pump Inhibitors:** No change to the clinical edit for continued high dose PPIs over three months

Allow Prevacid Soltab® without PA for persons under age 12

No other changes to current listings

**5HT 4 Agonists:** no change to current listing

#### **Ophthalmic Drug Classes**

**Glaucoma-Alpha 2 Adrenergics:** add generic bromonidine tartrate without PA

**Glaucoma-Beta Blockers:** no change to current listings

**Glaucoma-Prostaglandin Inhibitors:** no changes to current listings

**Glaucoma-Carbonic Anhydrase Inhibitors:** no change to current listings

**Ophthalmic Antihistamines:** remove PA from Patanol®

Add PA to Elestat® and Zaditor®

Allow existing patients on Elestat® and Zaditor® to continue to receive Rx without PA

**Ophthalmic Fluoroquinolones:** no change to current listings

**Ophthalmic Mast Cell Stabilizers:** no change to current listings

#### **Miscellaneous Drug Classes**

**Osteoporosis Agents:Bisphosphonates:** no change to current listings

**Osteoporosis Agents: Other:** no change to current listings

**Osteoporosis Agents: SERMS:** no change to current listing

**Serotonin Receptor Agonists:** add PA to Zomig®, Zomig ZMT®

Remove PA from Maxalt®, Maxalt MLT®

Do not require PA for existing patients on Zomig®, Zomig ZMT®

**Topical Immunomodulators:** no change to current listing

**Urinary Tract Antispasmodics:** remove PA from Vesicare®

Add PA to Detrol®, Oxytrol®

Do not require PA for existing patients on Detrol®, Oxytrol®

**Electrolyte Depleters:** no change to current listings

**Alpha Blockers for BPH:** no change to current listings

**Agents for Multiple Sclerosis:** no change to current listings

**Non-Ergot Dopamine Receptor Agonists:** no change to current listings

**Biologic Immunomodulators:** no change to current listings

**Addition of a new PDL Class:** *Ophthalmic NSAIDs*

The Committee reviewed this matter and recommends to the Department the following:

Add flurbiprofen sodium, Acular® and Voltaren® without PA

Require PA for Xibrom®, Nevanac® and Profenal®

**Public Comment**

The following individuals made comment to the Committee:

M. Goetting,MD, Lunesta®, and sleep disorders

J. VanHorn, PharmD, Takeda, Rozerem®, Amitiza®

B. Facca, PharmD, GSK, Imitrex®

M. Voorman, PharmD, JNJ, Ultram ER®

B. Mathew, PharmD, Sanofi, Ambien CR®

L. Pompe, MD, Pfizer, Lyrica®

G. Kouskoulas, MD, Concerta®

K. Foley, MD, Alzheimers disease and Aricept®

M. al Sheikh, MD, Celebrex®

**The next meeting will be Tuesday, December 5, 2006, 6PM, Kellogg Center**